New pill could tame deadly heart flutters during exercise
NCT ID NCT07263139
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new oral drug called AGP100 in people with a rare inherited heart condition (CPVT) that can cause dangerously fast heartbeats during stress or exercise. Ten adults aged 18-75 will take three different doses of AGP100 over six weeks while continuing their usual heart medications. Researchers will check if the drug is safe and helps maintain a normal heart rhythm during exercise.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AGP100 (oral capsule)
What this could lead to
If successful, AGP100 could offer a new treatment option to better control dangerous heart rhythms in people with CPVT, potentially improving their ability to exercise safely.
What could go wrong
This is a small, early-phase trial with only 10 participants, so results may not apply to everyone. The drug may cause side effects or fail to improve heart rhythm control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Cardiology, Oslo University Hospital
RECRUITINGOslo, Norway
Contact Phone: •••-•••-•••• Email: •••••@•••••